Description
Global Compounding Chemotherapy Market Overview
Market Dynamics
As per this report, Global Compounding Chemotherapy Market is anticipated to exhibit a CAGR of 6.04% during the review period of 2020 to 2027, to surpass USD 635.58 Million by 2027. The global market growth is driven by the surged incidences of cancer, increasing expenditure on medicine & science and reimbursements, and increased health benefits.
Further, the Compounding chemotherapy market is attributed to the emerging technical advancements, innovations, and strategies to cater to the demands of clinicians.
The global Compounding Chemotherapy Market is expected to witness substantial market growth owing to the highest market contribution in 2019. The rising opioid scarcity is predicted to increase the demand for compounding chemotherapy globally for compounding chemotherapy.
The growth of the market is driven by the benefits of easy-to-use medicines, allowing alternative dosage types to access expired medicines, and making medicines allergen safe. Additionally, hospitals and other healthcare providers are allowing customers to purchase medications that are compounded.
Stem Cell Therapy Market – Forecast till 2027
Market Segmentation
Global Compounding Chemotherapy Market has been classified in terms of Dose, Compounding Type, Delivery Method, Sterility, Technology, Compounder Type, and Application.
Global Compounding Chemotherapy Market in terms of the dose has been bifurcated into chemotherapeutic and non-chemotherapeutics. The global compounding chemotherapy market, by compounding type, has been classified into pharmaceutical ingredient alteration (PIA), currently unavailable pharmaceutical manufacturing (CUPM), and pharmaceutical dosage alteration (PDA).
The PDA segment is evaluated to register a fastest growth rate during the forecast period. Based on the delivery method, the global market has been divided into gravimetric automated compounding devices (weight-based) and volumetric automated compounding devices (volume-based).
Based on the global compounding chemotherapy market, has been bifurcated into sterile and non-sterile. The sterile is expected to lead the market owing to the largest share of 56.0% in 2019.
Regional Analysis
Region-specific analysis of Global Compounding Chemotherapy Market, based on region, has been classified into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The Americas is likely to drive the largest market owing to the surge in cancer patients, an increase in health care rates, and the growing requirement for treatment with chemotherapy in the area. The regional market has been classified into North America and Latin America, with the North American market further divided into the US and Canada.
The European compounding chemotherapy market has been classified into Western Europe and Eastern Europe. The Western Europe compounding chemotherapy market is spread across Germany, France, the UK, Italy, Spain, and the Rest of Western Europe.
The regional market has been driven by the government-based research program aimed at curing the rising number of cancer cases and increased health spending pushes the growth of the regional chemotherapy market.
Major Players
The Key Players in the Global Compounding Chemotherapy Market include Braun Melsungen AG, Pfizer Inc., Baxter, Grifols SA, The Metrix Company, Added Pharma, Equashield, Millers Pharmacy, Comecer S.P.A., Omnicell, Icon group, Dedalus Group, Arxium, Sterline S.R.L., and Loccioni.
COVID 19 Impacts
We are continuously tracking the impact of the COVID-19 pandemic on various industries and verticals within all domains. Our research reports include the same and help you understand the drop and rise, owing to the impact of COVID-19 on the industries.
Also, we help you to identify the gap between the demand and supply of your interested market. Moreover, the report helps you with the analysis, amended government regulations, and many other useful insights.
Table of Contents
TABLE OF CONTENT
1 EXECUTIVE SUMMARY
2 MARKET INTRODUCTION
2.1 DEFINITION 21
2.2 SCOPE OF THE STUDY 21
2.3 RESEARCH OBJECTIVE 21
2.4 MARKET STRUCTURE 22
2.5 ASSUMPTIONS & LIMITATIONS 23
3 RESEARCH METHODOLOGY
3.1 DATA MINING 24
3.2 SECONDARY RESEARCH 25
3.3 PRIMARY RESEARCH 26
3.4 BREAKDOWN OF PRIMARY RESPONDENTS 27
3.5 FORECASTING TECHNIQUES 28
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 29
3.6.1 BOTTOM-UP APPROACH 30
3.6.2 TOP-DOWN APPROACH 30
3.7 DATA TRIANGULATION 31
3.8 VALIDATION 31
4 MARKET DYNAMICS
4.1 OVERVIEW 32
4.2 DRIVERS 33
4.2.1 TECHNOLOGICAL DEVELOPMENTS AND GROUND-BREAKING TECHNIQUES 33
4.2.2 INCREASE IN DRUGS SHORTAGE COMPRISING CANCER MEDICINES 34
4.2.3 RISE IN AWARENESS AND ADAPTATION OF NEW TECHNOLOGIES AMONG CANCER HOSPITALS 34
4.2.4 RISING PREVALENCE OF CANCER PATIENTS 34
4.3 RESTRAINTS 36
4.3.1 DEARTH OF PRACTICED PHARMACISTS AND LAB TECHNICIANS 36
4.4 OPPORTUNITIES 36
4.4.1 NEW PRODUCT INNOVATIONS 36
4.4.2 RISE IN PARTNERSHIPS & COLLABORATIONS 36
5 MARKET FACTOR ANALYSIS
5.1 VALUE CHAIN ANALYSIS 37
5.1.1 R&D AND DESIGNING 37
5.1.2 MANUFACTURING 38
5.1.3 DISTRIBUTION & SALES 38
5.1.4 POST SALES SERVICES 38
5.2 PORTER’S FIVE FORCES MODEL 38
5.2.1 BARGAINING POWER OF SUPPLIERS 39
5.2.2 BARGAINING POWER OF BUYERS 39
5.2.3 THREAT OF NEW ENTRANTS 39
5.2.4 THREAT OF SUBSTITUTES 40
5.2.5 INTENSITY OF RIVALRY 40
5.3 COVID-19 IMPACT ANALYSIS 40
5.3.1 IMPACT ON SUPPLY CHAIN 41
5.3.2 IMPACT ON PRODUCTION 41
5.3.3 IMPACT ON REGIONS 41
5.3.4 DEMAND-SUPPLY GAP ANALYSIS 41
5.4 LIST OF POTENTIAL CUSTOMERS 42
6 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, BY DOSE
6.1 OVERVIEW 45
6.2 CHEMOTHERAPEUTIC 46
6.3 NON-CHEMOTHERAPEUTICS 46
7 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDING TYPE
7.1 OVERVIEW 47
7.2 PHARMACEUTICAL INGREDIENT ALTERATION (PIA) 48
7.3 CURRENTLY UNAVAILABLE PHARMACEUTICAL MANUFACTURING (CUPM) 49
7.4 PHARMACEUTICAL DOSAGE ALTERATION (PDA) 50
8 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, BY DELIVERY METHOD
8.1 OVERVIEW 51
8.2 GRAVIMETRIC AUTOMATED COMPOUNDING DEVICE (WEIGHT-BASED) 52
8.3 VOLUMETRIC AUTOMATED COMPOUNDING DEVICE (VOLUME-BASED) 53
9 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, BY STERILITY
9.1 OVERVIEW 54
9.2 STERILE 55
9.3 NON-STERILE 56
10 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, BY TECHNOLOGY
10.1 OVERVIEW 57
10.2 WITH ROBOTIC ARMS 58
10.3 WITHOUT ROBOTIC ARMS 59
11 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, BY COMPOUNDER TYPE
11.1 OVERVIEW 60
11.2 PHARMODUCT 61
11.3 EQUASHIELD PRO 61
11.4 MEDIMIX 61
11.5 INTEGRA 61
11.6 OTHERS 61
12 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, BY APPLICATION
12.1 OVERVIEW 62
12.2 BREAST CANCER 63
12.3 BLOOD CANCER 64
12.4 PROSTATE CANCER 65
12.5 GASTROINTESTINAL CANCER 66
12.6 RESPIRATORY/LUNG CANCER 66
12.7 OTHERS 67
13 GLOBAL COMPOUNDING CHEMOTHERAPY MARKET, BY REGION
13.1 OVERVIEW 68
13.2 AMERICAS 69
13.2.1 NORTH AMERICA 73
13.2.1.1 US 76
13.2.1.2 CANADA 79
13.2.2 LATIN AMERICA 82
13.2.2.1 BRAZIL 85
13.2.2.2 REST OF LATIN AMERICA 88
13.3 EUROPE 92
13.3.1 WESTERN EUROPE 96
13.3.1.1 GERMANY 99
13.3.1.2 FRANCE 102
13.3.1.3 UK 105
13.3.1.4 ITALY 108
13.3.1.5 SPAIN 111
13.3.1.6 REST OF WESTERN EUROPE 114
13.3.2 EASTERN EUROPE 117
13.4 ASIA-PACIFIC 121
13.4.1 CHINA 125
13.4.2 JAPAN 127
13.4.3 INDIA 130
13.4.4 AUSTRALIA 133
13.4.5 SOUTH KOREA 136
13.4.6 REST OF ASIA-PACIFIC 139
13.5 MIDDLE EAST & AFRICA 142
13.5.1 MIDDLE EAST 145
13.5.2 AFRICA 148
14 COMPETITIVE LANDSCAPE
14.1 OVERVIEW 151
14.2 COMPETITOR DASHBOARD 152
14.3 MAJOR GROWTH STRATEGY IN THE GLOBAL COMPOUNDING CHEMOTHERAPY MARKET 153
14.4 MARKET SHARE ANALYSIS 153
14.5 COMPETITIVE BENCHMARKING 154
14.6 THE LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL COMPOUNDING CHEMOTHERAPY MARKET 155
14.7 KEY DEVELOPMENTS & GROWTH STRATEGIES 156
14.8 KEY DEVELOPMENTS & GROWTH STRATEGIES 156
14.8.1 ACQUISITION 156
14.8.2 COLLABORATION 156
14.8.3 PARTNERSHIP 157
14.8.4 COLLABORATION 157
15 COMPANY PROFILE
15.1 B. BRAUN MELSUNGEN AG 158
15.1.1 COMPANY OVERVIEW 158
15.1.2 FINANCIAL OVERVIEW 158
15.1.3 PRODUCTS/SERVICES OFFERED 159
15.1.4 KEY DEVELOPMENTS 159
15.1.5 SWOT ANALYSIS 160
15.1.6 KEY STRATEGIES 160
15.2 PFIZER INC. 161
15.2.1 COMPANY OVERVIEW 161
15.2.2 FINANCIAL OVERVIEW 161
15.2.3 PRODUCTS/SERVICES OFFERED 162
15.2.4 KEY DEVELOPMENTS 162
15.2.5 SWOT ANALYSIS 162
15.2.6 KEY STRATEGIES 163
15.3 BAXTER 164
15.3.1 COMPANY OVERVIEW 164
15.3.2 FINANCIAL OVERVIEW 164
15.3.3 PRODUCTS/SERVICES OFFERED 165
15.3.4 KEY DEVELOPMENTS 165
15.3.5 SWOT ANALYSIS 165
15.3.6 KEY STRATEGIES 166
15.4 GRIFOLS, S.A. 167
15.4.1 COMPANY OVERVIEW 167
15.4.2 FINANCIAL OVERVIEW 167
15.4.3 PRODUCTS/SERVICES OFFERED 168
15.4.4 KEY DEVELOPMENTS 168
15.4.5 SWOT ANALYSIS 168
15.4.6 KEY STRATEGIES 169
15.5 THE METRIX COMPANY 170
15.5.1 COMPANY OVERVIEW 170
15.5.2 FINANCIAL OVERVIEW 170
15.5.3 PRODUCTS/SERVICES OFFERED 170
15.5.4 KEY DEVELOPMENTS 170
15.5.5 SWOT ANALYSIS 171
15.5.6 KEY STRATEGIES 171
15.6 ADDED PHARMA 172
15.6.1 COMPANY OVERVIEW 172
15.6.2 FINANCIAL OVERVIEW 172
15.6.3 PRODUCTS/SERVICES OFFERED 172
15.6.4 KEY DEVELOPMENTS 173
15.6.5 SWOT ANALYSIS 173
15.6.6 KEY STRATEGIES 173
15.7 EQUASHIELD 174
15.7.1 COMPANY OVERVIEW 174
15.7.2 FINANCIAL OVERVIEW 174
15.7.3 PRODUCTS/SERVICES OFFERED 174
15.7.4 KEY DEVELOPMENTS 174
15.7.5 SWOT ANALYSIS 175
15.7.6 KEY STRATEGIES 175
15.8 MILLERS PHARMACY 176
15.8.1 COMPANY OVERVIEW 176
15.8.2 FINANCIAL OVERVIEW 176
15.8.3 PRODUCTS/SERVICES OFFERED 176
15.8.4 KEY DEVELOPMENTS 176
15.8.5 SWOT ANALYSIS 177
15.8.6 KEY STRATEGIES 177
15.9 COMECER S.P.A. 178
15.9.1 COMPANY OVERVIEW 178
15.9.2 FINANCIAL OVERVIEW 178
15.9.3 PRODUCTS/SERVICES OFFERED 178
15.9.4 SWOT ANALYSIS 179
15.9.5 KEY STRATEGIES 179
15.10 OMNICELL 180
15.10.1 COMPANY OVERVIEW 180
15.10.2 FINANCIAL OVERVIEW 180
15.10.3 PRODUCTS/SERVICES OFFERED 180
15.10.4 SWOT ANALYSIS 181
15.10.5 KEY STRATEGIES 181
15.11 ICON GROUP 182
15.11.1 COMPANY OVERVIEW 182
15.11.2 FINANCIAL OVERVIEW 182
15.11.3 PRODUCTS/SERVICES OFFERED 182
15.11.4 KEY DEVELOPMENTS 183
15.11.5 SWOT ANALYSIS 184
15.11.6 KEY STRATEGIES 184
15.12 DEDALUS GROUP 185
15.12.1 COMPANY OVERVIEW 185
15.12.2 FINANCIAL OVERVIEW 185
15.12.3 PRODUCTS/SERVICES OFFERED 185
15.12.4 KEY DEVELOPMENTS 185
15.12.5 SWOT ANALYSIS 186
15.12.6 KEY STRATEGIES 186
15.13 ARXIUM 187
15.13.1 COMPANY OVERVIEW 187
15.13.2 FINANCIAL OVERVIEW 187
15.13.3 PRODUCTS/SERVICES OFFERED 187
15.13.4 KEY DEVELOPMENTS 187
15.13.5 SWOT ANALYSIS 188
15.13.6 KEY STRATEGIES 188
15.14 STERILINE S.R.L. 189
15.14.1 COMPANY OVERVIEW 189
15.14.2 FINANCIAL OVERVIEW 189
15.14.3 PRODUCTS/SERVICES OFFERED 189
15.14.4 KEY DEVELOPMENTS 189
15.14.5 SWOT ANALYSIS 190
15.14.6 KEY STRATEGIES 190
15.15 LOCCIONI 191
15.15.1 COMPANY OVERVIEW 191
15.15.2 PRODUCTS/SERVICES OFFERED 191
15.15.3 KEY DEVELOPMENTS 191
15.15.4 SWOT ANALYSIS 192
15.15.5 KEY STRATEGIES 192
16 APPENDIX
16.1 REFERENCES 193
16.2 RELATED REPORTS 193
